Thermo Fisher Scientific Inc (NYSE:TMO) – Equities research analysts at Leerink Swann decreased their Q4 2017 earnings per share estimates for Thermo Fisher Scientific in a note issued to investors on Monday. Leerink Swann analyst P. Souda now forecasts that the medical research company will earn $2.64 per share for the quarter, down from their previous estimate of $2.65. Leerink Swann has a “Outperform” rating and a $200.00 price target on the stock. Leerink Swann also issued estimates for Thermo Fisher Scientific’s Q4 2018 earnings at $2.81 EPS, FY2018 earnings at $10.38 EPS and Q1 2019 earnings at $2.62 EPS.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. During the same quarter in the prior year, the company earned $2.03 EPS. The company’s revenue was up 13.9% compared to the same quarter last year.

Other equities research analysts have also recently issued research reports about the stock. Cowen reaffirmed a “buy” rating and issued a $200.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, September 1st. Argus reissued a “buy” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, August 22nd. They noted that the move was a valuation call. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 target price for the company in a research report on Thursday, September 7th. Goldman Sachs Group began coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, September 26th. They set a “buy” rating and a $225.00 target price for the company. Finally, Deutsche Bank set a $226.00 target price on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Thursday, October 26th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $205.21.

Shares of Thermo Fisher Scientific (NYSE TMO) opened at $182.03 on Tuesday. Thermo Fisher Scientific has a 52-week low of $139.88 and a 52-week high of $201.20. The firm has a market cap of $77,071.31, a P/E ratio of 21.12, a PEG ratio of 1.76 and a beta of 1.06. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81.

The business also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be issued a $0.15 dividend. The ex-dividend date is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.19%.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total value of $9,419,500.00. Following the completion of the transaction, the chief executive officer now owns 252,577 shares of the company’s stock, valued at $47,582,981.03. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.49% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of Nova Scotia Trust Co. acquired a new stake in shares of Thermo Fisher Scientific in the third quarter worth $106,000. Proficio Capital Partners LLC increased its stake in shares of Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after acquiring an additional 253 shares during the period. Shine Investment Advisory Services Inc. acquired a new stake in shares of Thermo Fisher Scientific in the second quarter worth $113,000. Chicago Partners Investment Group LLC acquired a new stake in shares of Thermo Fisher Scientific in the second quarter worth $108,000. Finally, Ropes Wealth Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 15.8% in the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after acquiring an additional 97 shares during the period. 86.16% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Brokers Set Expectations for Thermo Fisher Scientific Inc’s Q4 2017 Earnings (TMO)” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/05/brokers-set-expectations-for-thermo-fisher-scientific-incs-q4-2017-earnings-tmo.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.